OSC

Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures

Retrieved on: 
Friday, March 29, 2024

Due to delays in the financial reporting process stemming from accounting and financial reporting impacts associated with the restructuring activities and transformation of the Company during the 2023 year, Anaergia’s audit will take additional time.

Key Points: 
  • Due to delays in the financial reporting process stemming from accounting and financial reporting impacts associated with the restructuring activities and transformation of the Company during the 2023 year, Anaergia’s audit will take additional time.
  • The Company is working diligently to facilitate the completion of the audit of the annual consolidated financial statements by Deloitte LLP and will be in a position to file the Required Documents on or about April 15, 2024.
  • Once issued, the CTO will remain in place until such time as the Required Documents are completed by the Company.
  • Other than as disclosed herein, Anaergia is up to date in its filing obligations.

Adtran FSP 3000 OLS plays key role in OIF’s largest-ever demo at OFC

Retrieved on: 
Friday, March 22, 2024

Adtran today announced that it’s playing a key role in the Optical Internetworking Forum’s (OIF) most extensive multi-vendor interoperability demo to date, held at the Optical Fiber Communication Conference and Exhibition (OFC).

Key Points: 
  • Adtran today announced that it’s playing a key role in the Optical Internetworking Forum’s (OIF) most extensive multi-vendor interoperability demo to date, held at the Optical Fiber Communication Conference and Exhibition (OFC).
  • Central to the showcase is Adtran’s FSP 3000 open line system (OLS), which delivers 400Gbit/s OpenZR+ transceiver interoperability across a 1,000km link.
  • View the full release here: https://www.businesswire.com/news/home/20240322753779/en/
    Adtran’s FSP 3000 OLS is playing a central role in the OIF’s biggest interoperability demo to date.
  • “This demo is a testament to the power of strategic collaboration and technological integration, epitomizing the core principles our FSP 3000 OLS was built upon: openness, scalability and cutting-edge performance.

OSC investor warnings and alerts for March 12-April 2, 2024

Retrieved on: 
Tuesday, April 2, 2024

TORONTO, April 2, 2024 /CNW/ - The Ontario Securities Commission (OSC) is warning Ontario investors that the following companies are not registered to deal or advise in securities in Ontario:

Key Points: 

TORONTO, April 2, 2024 /CNW/ - The Ontario Securities Commission (OSC) is warning Ontario investors that the following companies are not registered to deal or advise in securities in Ontario:

OSC opens registration for OSC Dialogue 2024

Retrieved on: 
Wednesday, March 20, 2024

TORONTO, March 20, 2024 /CNW/ - The Ontario Securities Commission (OSC) today opened registration for OSC Dialogue 2024: Inviting, thriving and secure capital markets.

Key Points: 
  • TORONTO, March 20, 2024 /CNW/ - The Ontario Securities Commission (OSC) today opened registration for OSC Dialogue 2024: Inviting, thriving and secure capital markets.
  • Cameron Schuler, Chief Commercialization Officer and Vice President, Industry Innovation, Vector Institute
    OSC Dialogue 2024 will take place on Wednesday, May 22, 2024, at the Metro Toronto Convention Centre.
  • For the latest updates on OSC Dialogue, please subscribe to our event updates , visit the OSC website , and follow #OSCDialogue on X and LinkedIn.
  • Investors are urged to check the registration of any persons or company offering an investment opportunity and to review the OSC investor materials available at http://www.osc.ca .

OSC investor warnings and alerts for February 20-March 12, 2024

Retrieved on: 
Tuesday, March 12, 2024

TORONTO, March 12, 2024 /CNW/ - The Ontario Securities Commission (OSC) is warning Ontario investors that the following companies are not registered to deal or advise in securities in Ontario:

Key Points: 

TORONTO, March 12, 2024 /CNW/ - The Ontario Securities Commission (OSC) is warning Ontario investors that the following companies are not registered to deal or advise in securities in Ontario:

OBSI announces new board members

Retrieved on: 
Friday, March 1, 2024

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:

Key Points: 
  • TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:
    Mary Condon has joined the board as a Consumer Interest Director.
  • Previously, she was a board member of the Capital Markets Authority Implementation Organization, and Commissioner and board member of the Ontario Securities Commission (OSC), where she was also a Vice-Chair.
  • All directors have a fiduciary duty to OBSI and do not advocate for or represent any outside interest while engaged in OBSI governance.
  • If a consumer has a complaint against an OBSI participating bank or investment firm that they are not able to resolve with the bank or firm, OBSI will investigate at no cost to the consumer.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Wednesday, March 6, 2024

VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

OSC awards $1.5 million to whistleblower

Retrieved on: 
Tuesday, February 27, 2024

TORONTO, Feb. 27, 2024 /CNW/ - The Ontario Securities Commission (OSC) issued an award of CAD $1,500,000 to a whistleblower who provided information which allowed the OSC to act swiftly to protect investors from harm.

Key Points: 
  • TORONTO, Feb. 27, 2024 /CNW/ - The Ontario Securities Commission (OSC) issued an award of CAD $1,500,000 to a whistleblower who provided information which allowed the OSC to act swiftly to protect investors from harm.
  • The whistleblower was an insider and submitted very specific and discrete non-public information to the OSC that broadened the scope of an existing investigation and contributed to the successful enforcement action.
  • "The whistleblower had access to valuable information regarding early-stage misconduct that was critical to our ability to quickly respond and protect investors from further harm," said Jeff Kehoe, Director of Enforcement at the OSC.
  • The OSC Whistleblower Program offers protections for individuals who come forward with information about potential violations of Ontario securities law and awards up to $5 million for tips that lead to successful enforcement action.